Evaluating the quantity, quality and size distribution of cell-free DNA by multiplex droplet digital PCR.

Published on Jul 28, 2020in Scientific Reports3.998
· DOI :10.1038/S41598-020-69432-X
Miguel Alcaide27
Estimated H-index: 27
(SFU: Simon Fraser University),
Matthew Cheung3
Estimated H-index: 3
(SFU: Simon Fraser University)
+ 8 AuthorsRyan D. Morin53
Estimated H-index: 53
(SFU: Simon Fraser University)
Sources
Abstract
Cell-free DNA (cfDNA) has become a comprehensive biomarker in the fields of non-invasive cancer detection and monitoring, organ transplantation, prenatal genetic testing and pathogen detection. While cfDNA samples can be obtained using a broad variety of approaches, there is an urgent need to standardize analytical tools aimed at assessing its basic properties. Typical methods to determine the yield and fragment size distribution of cfDNA samples are usually either blind to genomic DNA contamination or the presence of enzymatic inhibitors, which can confound and undermine downstream analyses. Here, we present a novel droplet digital PCR assay to identify suboptimal samples and aberrant cfDNA size distributions, the latter typically associated with high levels of circulating tumour DNA (ctDNA). Our assay was designed to promiscuously cross-amplify members of the human olfactory receptor (OR) gene family and includes a customizable diploid locus for the determination of absolute cfDNA concentrations. We demonstrate here the utility of our assay to estimate the yield and quality of cfDNA extracts and deduce fragment size distributions that correlate well with those inferred by capillary electrophoresis and high throughput sequencing. The assay described herein is a powerful tool to establish quality controls and stratify cfDNA samples based on presumed ctDNA levels, then facilitating the implementation of robust, cost-effective and standardized analytical workflows into clinical practice.
📖 Papers frequently viewed together
9 Citations
39 Citations
1 Author (Eva Graf)
References40
Newest
#1Stephen Cristiano (Johns Hopkins University)H-Index: 5
#2Alessandro Leal (Johns Hopkins University)H-Index: 7
Last. Victor E. Velculescu (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 106
view all 36 authors...
Cell-free DNA in the blood provides a non-invasive diagnostic avenue for patients with cancer1. However, characteristics of the origins and molecular features of cell-free DNA are poorly understood. Here we developed an approach to evaluate fragmentation patterns of cell-free DNA across the genome, and found that profiles of healthy individuals reflected nucleosomal patterns of white blood cells, whereas patients with cancer had altered fragmentation profiles. We used this method to analyse the ...
241 CitationsSource
#1Benjamin Arko-Boham (University of Ghana)H-Index: 3
#2Nii Ayite Aryee (College of Health Sciences, Bahrain)H-Index: 3
Last. Nii Armah Adu-Aryee (College of Health Sciences, Bahrain)H-Index: 2
view all 8 authors...
Abstract Background Cancer incidence and its related mortality is rising and is currently the second leading cause of death globally. In Africa, breast and prostate cancer in females and males, respectively, are the worst globally. However, biomarkers for their early detection and prognosis are not well developed. This study sought to investigate circulating cell-free DNA (ccfDNA) integrity and its potential utility as diagnostic and/or prognostic biomarker. Circulating cell-free DNA (ccfDNA) is...
16 CitationsSource
#1Karen Page (Leicester Royal Infirmary)H-Index: 13
#2Jacqueline A. Shaw (Leicester Royal Infirmary)H-Index: 21
Last. David S. Guttery (Leicester Royal Infirmary)H-Index: 25
view all 3 authors...
12 CitationsSource
#1Romain MeddebH-Index: 5
#2Ekaterina PisarevaH-Index: 1
Last. Alain R. ThierryH-Index: 39
view all 3 authors...
Circulating cell-free DNA (cfDNA) isolated from blood has been identified as a potential biomarker in numerous fields, and has been the object of intensive research over the past decade, although its original discovery dates back 60 years. While it is already used routinely in commercial and clinical practice in oncology and prenatal testing, other potential applications have emerged, including for diabetes, cardiovascular diseases, organ transplantation, autoimmune diseases, sepsis, trauma, and...
55 CitationsSource
#1Gustav Johansson (AstraZeneca)H-Index: 3
#2Daniel Andersson (University of Gothenburg)H-Index: 14
Last. Anders Ståhlberg (University of Gothenburg)H-Index: 40
view all 7 authors...
Abstract Circulating cell-free tumor DNA (ctDNA) is a promising biomarker in cancer. Ultrasensitive technologies enable detection of low (
40 CitationsSource
#2Simone A. Thair (Stanford University)H-Index: 13
Last. Samuel Yang (Stanford University)H-Index: 32
view all 23 authors...
Thousands of pathogens are known to infect humans, but only a fraction are readily identifiable using current diagnostic methods. Microbial cell-free DNA sequencing offers the potential to non-invasively identify a wide range of infections throughout the body, but the challenges of clinical-grade metagenomic testing must be addressed. Here we describe the analytical and clinical validation of a next-generation sequencing test that identifies and quantifies microbial cell-free DNA in plasma from ...
193 CitationsSource
#1Simon R. Knight (University of Oxford)H-Index: 24
#2Adam Thorne (University of Oxford)H-Index: 1
Last. Maria Letizia Lo Faro (University of Oxford)H-Index: 2
view all 3 authors...
BackgroundThere is increasing interest in the use of noninvasive biomarkers to reduce the risks posed by invasive biopsy for monitoring of solid organ transplants (SOTs). One such promising marker is the presence of donor-derived cell-free DNA (dd-cfDNA) in the urine or blood of transplant recipient
65 CitationsSource
: Cell-free DNA integrity (cfDNAi) could be a valuable biomarker for solid tumors, to define prognosis and response to therapy. Several elements have been studied for cfDNAi, such as specific genes involved in cancer progression or repetitive DNA sequences as surrogate markers for the whole circulating DNA.However, the lack of a standardized method for cfDNAi evaluation remains one of its main critical issues. Apoptotic index (AI) and integrity index (II) of cfDNA could be useful biomarkers to i...
2 CitationsSource
#1Miguel Alcaide (SFU: Simon Fraser University)H-Index: 27
#2Christopher Rushton (SFU: Simon Fraser University)H-Index: 8
Last. Ryan D. Morin (SFU: Simon Fraser University)H-Index: 53
view all 3 authors...
: Liquid biopsies are rapidly emerging as powerful tools for the early detection of cancer, noninvasive genomic profiling of localized or metastatic tumors, prompt detection of treatment resistance-associated mutations, and monitoring of therapeutic response and minimal residual disease in patients during clinical follow-up. Growing evidence strongly supports the utility of circulating tumor DNA (ctDNA) as a biomarker for the stratification and clinical management of lymphoma patients. However, ...
5 CitationsSource
#1Filippo Martignano (UNISI: University of Siena)H-Index: 10
#1Filippo Martignano (UNISI: University of Siena)H-Index: 3
: The study of cell-free DNA (cfDNA) is often challenging due to genomic DNA contamination, low concentration, and high fragmentation. Therefore, it is important to optimize pre-analytical and analytical procedures in order to maximize the performance of cfDNA-based analyses.In this chapter, we report the most common methods for the correct collection, centrifugation, storage, and DNA isolation from cell-free biological sources such as plasma, urines, cerebrospinal fluid, and pleural effusion fl...
13 CitationsSource
Cited By12
Newest
#1Amanda G. Blouin (MSK: Memorial Sloan Kettering Cancer Center)
#2Fei Ye (MSK: Memorial Sloan Kettering Cancer Center)
Last. Medhat Z. Askar (Texas A&M Health Science Center College of Medicine)H-Index: 1
view all 0 authors...
BACKGROUND AND PURPOSE Currently there are no widely accepted guidelines for chimerism analysis testing in hematopoietic cell transplantation (HCT) patients. The objective of this review is to provide a practical guide to address key aspects of performing and utilizing chimerism testing results. In developing this guide, we conducted a survey of testing practices among laboratories that are accredited for performing engraftment monitoring/chimerism analysis by either the American Society for His...
Source
#1Kavita Thakur (Tel Aviv Sourasky Medical Center)
#1Kavita ThakurH-Index: 1
Last. Shlomo Tsuriel (Tel Aviv Sourasky Medical Center)
view all 6 authors...
Liquid biopsy has emerged as a promising non-invasive way to diagnose tumor and monitor its progression. Different types of liquid biopsies have different advantages and limitations. In the present research, we compared the use of two types of liquid biopsy, extracellular vesicle-derived DNA (EV-DNA) and cell-free DNA (cfDNA) for identifying tumor mutations in patients with colon carcinoma. Method: DNA was extracted from the tumor tissue of 33 patients diagnosed with colon carcinoma. Targeted NG...
Source
#1Elodie Bohers (French Institute of Health and Medical Research)H-Index: 19
#2Pierre-Julien Viailly (French Institute of Health and Medical Research)H-Index: 16
Last. Fabrice Jardin (French Institute of Health and Medical Research)H-Index: 48
view all 3 authors...
In the era of precision medicine, it is crucial to identify molecular alterations that will guide the therapeutic management of patients. In this context, circulating tumoral DNA (ctDNA) released by the tumor in body fluids, like blood, and carrying its molecular characteristics is becoming a powerful biomarker for non-invasive detection and monitoring of cancer. Major recent technological advances, especially in terms of sequencing, have made possible its analysis, the challenge still being its...
Source
#1Elizabeth GreenH-Index: 3
Last. Ashish M. Kamat (University of Texas MD Anderson Cancer Center)H-Index: 76
view all 8 authors...
Abstract Context Bladder and kidney cancers require invasive procedures for definitive diagnosis, and bladder cancer requires repeated procedures to monitor for disease recurrence. Given the recent work to identify molecular alterations in liquid biopsies to diagnose and monitor these diseases, a synthesis of the growing body of evidence is merited. Objective To review current data on cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) and to synthesize their roles in the diagnosis, monitori...
1 CitationsSource
#1Vida Ungerer (TUM: Technische Universität München)H-Index: 6
#2Abel Jacobus Bronkhorst (TUM: Technische Universität München)H-Index: 11
Last. Stefan Holdenrieder (TUM: Technische Universität München)H-Index: 36
view all 5 authors...
Recent advances in basic research have unveiled several strategies for improving the sensitivity and specificity of cell-free DNA (cfDNA) based assays, which is a prerequisite for broadening its clinical use. Included among these strategies is leveraging knowledge of both the biogenesis and physico-chemical properties of cfDNA towards the identification of better disease-defining features and optimization of methods. While good progress has been made on this front, much of cfDNA biology remains ...
Source
#1Lucien A.E. JackyH-Index: 3
Last. Aditya Rajagopal (California Institute of Technology)H-Index: 1
view all 7 authors...
Digital PCR (dPCR) is the gold standard analytical platform for rapid high precision quantification of genomic fragments. However, current dPCR assays are generally limited to monitoring 1-2 analytes per sample, thereby limiting the platforms ability to address some clinical applications that require the simultaneous monitoring of 20 - 50 analytes per sample. Here we present Virtual Partition dPCR (VPdPCR), a novel analysis methodology enabling the detection of 10 or more target regions per colo...
Source
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/associated nuclease (Cas) systems have repeatedly shown to have excellent performance in nucleotide sensing applications1-5. High specificity and selectivity of Cas effector proteins is determined by the CRISPR RNAs (crRNAs) interchangeable spacer sequence, as well as position and number of mismatches between target sequence and the crRNA sequence1. Some diseases are characterized by epigenetic alterations rather than nucleotide ...
Source
Neuroblastoma (NB) is an aggressive infancy tumor, leading cause of death among preschool age diseases. Here we focused on characterization of exosomal DNA (exo-DNA) isolated from plasma cell-derived exosomes of neuroblastoma patients, and its potential use for detection of somatic mutations present in the parental tumor cells. Exosomes are small extracellular membrane vesicles secreted by most cells, playing an important role in intercellular communications. Using an enzymatic method, we provid...
1 CitationsSource
#1Karen Gambaro (JGH: Jewish General Hospital)H-Index: 2
#2Maud Marques (JGH: Jewish General Hospital)H-Index: 12
Last. Gerald Batist (JGH: Jewish General Hospital)H-Index: 64
view all 26 authors...
BACKGROUND Therapeutic resistance is the main cause of death in metastatic colorectal cancer. To investigate genomic plasticity, most specifically of metastatic lesions, associated with response to first-line systemic therapy, we collected longitudinal liver metastatic samples and characterized the copy number aberration (CNA) landscape and its effect on the transcriptome. METHODS Liver metastatic biopsies were collected prior to treatment (pre, n = 97) and when clinical imaging demonstrated the...
Source
#1Phetploy Rungkamoltip (Thailand National Science and Technology Development Agency)
#2Sasithon TemisakH-Index: 3
Last. Tawin Iempridee (Thailand National Science and Technology Development Agency)H-Index: 9
view all 10 authors...
Circulating cell-free DNA (cfDNA) has attracted attention as a non-invasive biomarker for diagnosing and monitoring various cancers. Given that human papillomavirus (HPV) DNA integration and overex...
Source